IL163579A0 - Pharmaceutical compositions comprising one or moresteroids oneor more tetrahydrofolate components and vitamin B12 - Google Patents

Pharmaceutical compositions comprising one or moresteroids oneor more tetrahydrofolate components and vitamin B12

Info

Publication number: IL163579A0
Authority: IL; Israel
Prior art keywords: tetrahydrofolic acid; vitamin; tetrahydrofolic; dosage units; tetrahydrofolate components
Prior art date: 2002-02-21

Application number

IL16357902A

Other languages

English (en)

Original Assignee

Schering Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-02-21

Filing date

2002-11-15

Publication date

2005-12-18

2002-11-15 Application filed by Schering Ag filed Critical Schering Ag

2005-12-18 Publication of IL163579A0 publication Critical patent/IL163579A0/xx

Links

MSTNYGQPCMXVAQ-RYUDHWBXSA-N (6S)-5,6,7,8-tetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-RYUDHWBXSA-N 0.000 title abstract 4
239000005460 tetrahydrofolate Substances 0.000 title abstract 3
229930003779 Vitamin B12 Natural products 0.000 title 1
FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
239000011715 vitamin B12 Substances 0.000 title 1
235000019163 vitamin B12 Nutrition 0.000 title 1
238000000034 method Methods 0.000 abstract 3
MSTNYGQPCMXVAQ-KIYNQFGBSA-N 5,6,7,8-tetrahydrofolic acid Chemical class N1C=2C(=O)NC(N)=NC=2NCC1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 MSTNYGQPCMXVAQ-KIYNQFGBSA-N 0.000 abstract 2
FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 abstract 2
239000003433 contraceptive agent Substances 0.000 abstract 2
238000002657 hormone replacement therapy Methods 0.000 abstract 2
150000003431 steroids Chemical class 0.000 abstract 2
229940045999 vitamin b 12 Drugs 0.000 abstract 2
QYNUQALWYRSVHF-OLZOCXBDSA-N (6R)-5,10-methylenetetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C1)N)N1C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QYNUQALWYRSVHF-OLZOCXBDSA-N 0.000 abstract 1
VVIAGPKUTFNRDU-STQMWFEESA-N (6S)-5-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C=O)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-STQMWFEESA-N 0.000 abstract 1
ZNOVTXRBGFNYRX-STQMWFEESA-N (6S)-5-methyltetrahydrofolic acid Chemical compound C([C@@H]1N(C=2C(=O)N=C(N)NC=2NC1)C)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 ZNOVTXRBGFNYRX-STQMWFEESA-N 0.000 abstract 1
AUFGTPPARQZWDO-YPMHNXCESA-N 10-formyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1)N)N(C=O)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 AUFGTPPARQZWDO-YPMHNXCESA-N 0.000 abstract 1
YCWUVLPMLLBDCU-STQMWFEESA-N 5-formimidoyltetrahydrofolic acid Chemical compound C([C@H]1CNC=2N=C(NC(=O)C=2N1C=N)N)NC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 YCWUVLPMLLBDCU-STQMWFEESA-N 0.000 abstract 1
229940011871 estrogen Drugs 0.000 abstract 1
239000000262 estrogen Substances 0.000 abstract 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 abstract 1
239000000583 progesterone congener Substances 0.000 abstract 1
229940095055 progestogen systemic hormonal contraceptives Drugs 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Reproductive Health (AREA)
Molecular Biology (AREA)
Gynecology & Obstetrics (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Steroid Compounds (AREA)

IL16357902A 2002-02-21 2002-11-15 Pharmaceutical compositions comprising one or moresteroids oneor more tetrahydrofolate components and vitamin B12 IL163579A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02075695		2002-02-21
PCT/NL2002/000741 WO2003070255A1 (fr)	2002-02-21	2002-11-15	Compositions pharmaceutiques contenant un ou plusieurs steroides, un ou plusieurs tetrahydrofolates et de la vitamine b12

Publications (1)

Publication Number	Publication Date
IL163579A0 true IL163579A0 (en)	2005-12-18

Family

ID=27741182

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL16357902A IL163579A0 (en)	2002-02-21	2002-11-15	Pharmaceutical compositions comprising one or moresteroids oneor more tetrahydrofolate components and vitamin B12
IL163579A IL163579A (en)	2002-02-21	2004-08-17	Kit for use in hormonal contraceptive method or hormone replacement therapy

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL163579A IL163579A (en)	2002-02-21	2004-08-17	Kit for use in hormonal contraceptive method or hormone replacement therapy

Country Status (28)

Country	Link
US (1)	US20050164977A1 (fr)
EP (1)	EP1478373B1 (fr)
JP (1)	JP5037779B2 (fr)
KR (1)	KR100936827B1 (fr)
CN (1)	CN1620302B (fr)
AT (1)	ATE341333T1 (fr)
AU (1)	AU2002343249B2 (fr)
BR (1)	BR0215613A (fr)
CA (1)	CA2476940C (fr)
CR (1)	CR7420A (fr)
CY (1)	CY1106273T1 (fr)
DE (1)	DE60215224T2 (fr)
DK (1)	DK1478373T3 (fr)
EA (1)	EA007599B1 (fr)
EC (1)	ECSP045305A (fr)
ES (1)	ES2274107T3 (fr)
HU (1)	HUP0402674A3 (fr)
IL (2)	IL163579A0 (fr)
ME (1)	MEP37208A (fr)
MX (1)	MXPA04008185A (fr)
NO (1)	NO20043932L (fr)
NZ (1)	NZ534806A (fr)
PL (1)	PL209558B1 (fr)
PT (1)	PT1478373E (fr)
RS (1)	RS50909B (fr)
UA (1)	UA80965C2 (fr)
WO (1)	WO2003070255A1 (fr)
ZA (1)	ZA200407545B (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE102005023301B4 (de) *	2005-05-13	2012-05-31	Bayer Schering Pharma Aktiengesellschaft	Pharmazeutische Zusammensetzung enthaltend Gestagene und/oder Estrogene und 5-Methyl-(6S)-tetrahydrofolat
AU2012227235B2 (en) *	2005-05-13	2015-06-11	Bayer Intellectual Property Gmbh	Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl-(6S)-tetrahydrofolate
US20060293295A1 (en) *	2005-05-13	2006-12-28	Kai Strothmann	Pharmaceutical composition comprising progestogens and/or estrogens and 5-methyl- (6S)-tetrahydrofolate
UY29527A1 (es) *	2005-05-13	2006-12-29	Schering Ag	Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
EP1891959A1 (fr) *	2006-08-14	2008-02-27	Bayer Schering Pharma Aktiengesellschaft	Préparations contraceptives pour diminuer le risque d'erreurs innées
US8617597B2 (en) *	2006-07-06	2013-12-31	Bayer Intellectual Property Gmbh	Pharmaceutical composition containing a tetrahydrofolic acid
DE112007001600A5 (de) *	2006-07-06	2009-04-30	Bayer Schering Pharma Aktiengesellschaft	Pharmazeutische Zusammensetzung zur Kontrazeption und zur Verminderung des Risikos angeborener Fehlbildungen
CN101489563A (zh) *	2006-07-06	2009-07-22	拜耳先灵医药股份有限公司	用于避孕和预防先天性畸形风险的药物制剂
AU2013202756B2 (en) *	2006-07-06	2015-06-04	Bayer Intellectual Property Gmbh	Pharmaceutical composition containing a tetrahydrofolic acid
GB0715502D0 (en) *	2007-08-08	2007-09-19	Univ Manchester	Methods
EP2249803A2 (fr) *	2008-02-13	2010-11-17	Bayer Schering Pharma Aktiengesellschaft	Système de distribution de médicaments contenant de l'oestradiol
UY32836A (es)	2009-08-12	2011-03-31	Bayer Schering Pharma Ag	Partículas estabilizadas que comprenden 5-metil-(6s)-tetrahidrofolato
EP2324832B2 (fr) *	2009-11-09	2016-11-30	Biogena Naturprodukte GmbH & Co KG	Complément alimentaire lors d'une prise de contraceptifs hormonaux
BR112013030833B1 (pt)	2011-06-01	2019-09-03	Estetra S A	processo para a preparação de um composto de fórmula (i) e processo para a preparação de estetrol
WO2012164096A1 (fr)	2011-06-01	2012-12-06	Estetra S.A.	Procédé pour la production d'intermédiaires d'estétrol
EP2383279A1 (fr)	2011-07-19	2011-11-02	Pantarhei Bioscience B.V.	Procédé de préparation d'estetrol
US10357496B2 (en) *	2011-11-05	2019-07-23	South Alabama Medical Science Foundation	Methods, formulations, and kits for rapidly repleting folate levels in women
US9301920B2 (en)	2012-06-18	2016-04-05	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
RS62297B1 (sr)	2011-11-23	2021-09-30	Therapeuticsmd Inc	Prirodne kombinovane hormonske supstitucione formulacije i terapije
US20130338122A1 (en)	2012-06-18	2013-12-19	Therapeuticsmd, Inc.	Transdermal hormone replacement therapies
US10806697B2 (en)	2012-12-21	2020-10-20	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en)	2012-06-18	2015-07-16	Therapeuticsmd, Inc.	Progesterone formulations having a desirable pk profile
US10806740B2 (en)	2012-06-18	2020-10-20	Therapeuticsmd, Inc.	Natural combination hormone replacement formulations and therapies
US11266661B2 (en)	2012-12-21	2022-03-08	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en)	2012-12-21	2022-02-15	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en)	2012-12-21	2019-11-12	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en)	2012-12-21	2015-11-10	Therapeuticsmd, Inc.	Soluble estradiol capsule for vaginal insertion
US10568891B2 (en)	2012-12-21	2020-02-25	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en)	2012-12-21	2020-01-21	Therapeuticsmd, Inc.	Vaginal inserted estradiol pharmaceutical compositions and methods
HUE035848T2 (en) *	2013-12-12	2018-05-28	Donesta Bioscience B V	Solid dispensing unit containing an estetrol compound in the mouth
RU2016143081A (ru)	2014-05-22	2018-06-26	Терапьютиксмд, Инк.	Натуральные комбинированные гормонозаместительные составы и терапии
RS57328B1 (sr)	2015-06-18	2018-08-31	Mithra Pharmaceuticals S A	Orodisperzibilna dozna jedinica koja sadrži estetrolsku komponentu
WO2016203044A1 (fr)	2015-06-18	2016-12-22	Mithra Pharmaceuticals S.A.	Comprimé orodispersible contenant de l'estétrol
NZ737945A (en) *	2015-06-18	2023-06-30	Estetra Sprl	Orodispersible dosage unit containing an estetrol component
LT3310345T (lt)	2015-06-18	2021-06-25	Estetra Sprl	Burnoje disperguojama tabletė, turinti estetrolio
US10328087B2 (en)	2015-07-23	2019-06-25	Therapeuticsmd, Inc.	Formulations for solubilizing hormones
US10286077B2 (en)	2016-04-01	2019-05-14	Therapeuticsmd, Inc.	Steroid hormone compositions in medium chain oils
US9931349B2 (en)	2016-04-01	2018-04-03	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical composition
CA3178291A1 (fr)	2016-08-05	2018-04-12	Estetra Srl	Methode de prise en charge de la dysmenorrhee et des douleurs menstruelles
TWI801561B (zh)	2018-04-19	2023-05-11	比利時商依思特拉私人有限責任公司	化合物及其用於緩解絕經相關症狀的用途
CR20200486A (es)	2018-04-19	2021-01-27	Estetra Sprl	Compuestos y sus usos para aliviar los síntomas asociados a la menopausa
US11633405B2 (en)	2020-02-07	2023-04-25	Therapeuticsmd, Inc.	Steroid hormone pharmaceutical formulations
TWI893101B (zh)	2020-04-16	2025-08-11	比利時商埃斯特拉有限責任公司	具有降低之副作用之避孕組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1122456C (zh) *	1996-01-31	2003-10-01	南亚拉巴马医学科学基金会	含有天然的还原叶酸盐异构体的食品和维生素制品
JP2002514170A (ja) *	1996-07-30	2002-05-14	エナージェティクス，インコーポレイティド	食品補充物
WO1998011900A2 (fr) *	1996-09-18	1998-03-26	Sarill William J	Compositions contenant de la cobalamine et des acides amines
US6220453B1 (en) *	1998-04-07	2001-04-24	Fuji Photo Film Co., Ltd.	Blood filter unit
CN1240387C (zh) *	1998-04-17	2006-02-08	奥索一麦克尼尔药品公司	含有叶酸的药用组合物及其用途和给药系统
WO1999065337A1 (fr) *	1998-06-19	1999-12-23	Beth Israel Deaconess Medical Center	Complement dietetique destine aux femmes menopausees
US6479545B1 (en) *	1999-09-30	2002-11-12	Drugtech Corporation	Formulation for menopausal women
DE10022510A1 (de) *	2000-05-10	2001-11-15	Basf Ag	Zusammensetzungen enthaltend Folsäure und reduziertes Folat
BG104880A (en) *	2000-10-24	2002-04-30	Иван ХРИСТОВ	Medicamentous preparation for multiple sclerosis treatment

2002
- 2002-11-15 CA CA2476940A patent/CA2476940C/fr not_active Expired - Fee Related
- 2002-11-15 CN CN028282809A patent/CN1620302B/zh not_active Expired - Fee Related
- 2002-11-15 ES ES02780174T patent/ES2274107T3/es not_active Expired - Lifetime
- 2002-11-15 RS YUP-733/04A patent/RS50909B/sr unknown
- 2002-11-15 WO PCT/NL2002/000741 patent/WO2003070255A1/fr not_active Ceased
- 2002-11-15 DK DK02780174T patent/DK1478373T3/da active
- 2002-11-15 BR BR0215613-0A patent/BR0215613A/pt not_active IP Right Cessation
- 2002-11-15 AU AU2002343249A patent/AU2002343249B2/en not_active Ceased
- 2002-11-15 PT PT02780174T patent/PT1478373E/pt unknown
- 2002-11-15 MX MXPA04008185A patent/MXPA04008185A/es active IP Right Grant
- 2002-11-15 AT AT02780174T patent/ATE341333T1/de active
- 2002-11-15 PL PL371441A patent/PL209558B1/pl not_active IP Right Cessation
- 2002-11-15 NZ NZ534806A patent/NZ534806A/en not_active IP Right Cessation
- 2002-11-15 EP EP02780174A patent/EP1478373B1/fr not_active Expired - Lifetime
- 2002-11-15 HU HU0402674A patent/HUP0402674A3/hu unknown
- 2002-11-15 EA EA200401014A patent/EA007599B1/ru not_active IP Right Cessation
- 2002-11-15 ME MEP-372/08A patent/MEP37208A/xx unknown
- 2002-11-15 US US10/505,555 patent/US20050164977A1/en not_active Abandoned
- 2002-11-15 IL IL16357902A patent/IL163579A0/xx active IP Right Grant
- 2002-11-15 JP JP2003569211A patent/JP5037779B2/ja not_active Expired - Fee Related
- 2002-11-15 UA UA20040907578A patent/UA80965C2/uk unknown
- 2002-11-15 DE DE60215224T patent/DE60215224T2/de not_active Expired - Lifetime
- 2002-11-15 KR KR1020047012983A patent/KR100936827B1/ko not_active Expired - Fee Related
2004
- 2004-08-17 IL IL163579A patent/IL163579A/en not_active IP Right Cessation
- 2004-08-20 CR CR7420A patent/CR7420A/es not_active Application Discontinuation
- 2004-09-20 NO NO20043932A patent/NO20043932L/no not_active Application Discontinuation
- 2004-09-20 ZA ZA200407545A patent/ZA200407545B/en unknown
- 2004-09-21 EC EC2004005305A patent/ECSP045305A/es unknown
2006
- 2006-11-30 CY CY20061101724T patent/CY1106273T1/el unknown

Also Published As

Publication number	Publication date
PL209558B1 (pl)	2011-09-30
US20050164977A1 (en)	2005-07-28
HUP0402674A3 (en)	2012-12-28
EP1478373B1 (fr)	2006-10-04
MXPA04008185A (es)	2004-11-26
EA007599B1 (ru)	2006-12-29
KR20040094711A (ko)	2004-11-10
ZA200407545B (en)	2006-06-28
CN1620302B (zh)	2011-04-27
HK1078780A1 (en)	2006-03-24
JP5037779B2 (ja)	2012-10-03
DE60215224T2 (de)	2007-08-23
CR7420A (es)	2006-02-06
NZ534806A (en)	2006-05-26
RS73304A (sr)	2007-02-05
JP2005523283A (ja)	2005-08-04
EP1478373A1 (fr)	2004-11-24
NO20043932L (no)	2004-11-19
CY1106273T1 (el)	2011-10-12
RS50909B (sr)	2010-08-31
AU2002343249B2 (en)	2009-02-05
KR100936827B1 (ko)	2010-01-14
CA2476940A1 (fr)	2003-08-28
PT1478373E (pt)	2007-01-31
MEP37208A (en)	2011-02-10
PL371441A1 (en)	2005-06-13
HUP0402674A2 (hu)	2005-04-28
BR0215613A (pt)	2004-12-07
DE60215224D1 (de)	2006-11-16
UA80965C2 (en)	2007-11-26
AU2002343249A1 (en)	2003-09-09
IL163579A (en)	2011-03-31
ECSP045305A (es)	2004-10-26
WO2003070255A1 (fr)	2003-08-28
CA2476940C (fr)	2011-11-01
DK1478373T3 (da)	2007-01-15
ES2274107T3 (es)	2007-05-16
EA200401014A1 (ru)	2006-10-27
CN1620302A (zh)	2005-05-25
ATE341333T1 (de)	2006-10-15

Legal Events

Date	Code	Title	Description
2011-07-31	FF	Patent granted
2011-08-31	KB	Patent renewed

Publication	Publication Date	Title
PL371441A1 (en)	2005-06-13	Pharmaceutical compositions comprising one or more steroids one or more tetrahydrofolate components and vitamin b12
AU739544B2 (en)	2001-10-18	The use of tetrahydrofolates in natural stereoisomeric form for the production of a pharmaceutical preparation suitable for the influencing the homocysteine level, particularly for assisting the remethylation of homocysteine
CN101489563A (zh)	2009-07-22	用于避孕和预防先天性畸形风险的药物制剂
EP1071428A2 (fr)	2001-01-31	Compositions pharmaceutiques contenant de l'acide folique, procedes et systemes d'administration correspondants
US20080268048A1 (en)	2008-10-30	Pharmaceutical composition for contraception and for reducing the risk of congenital abnormalities
CL2009002187A1 (es)	2010-10-01	Composicion farmaceutica anticonceptiva que comprende 5-metil-(6s)-tetrahidrofolato, estrogenos y/o progestagenos, opcionalmente vitamina b6 y/o vitamina b2 y coadyuvantes/vehiculos; kit; proceso para prepararla; uso para reducir el riesgo de enfermedades y malformaciones congenitas por carencia de folato (div. sol. 1130-06).
WO2006099233B1 (fr)	2007-06-28	Compositions et methodes pour le traitement de l'osteoporose et des maladies articulaires inflammatoires
CA2696030A1 (fr)	2009-03-05	Utilisation de gestagenes en combinaison avec du (6s)-5-methyltetrahydrofolate pour le traitement de l'endometriose avec reduction simultanee d'effets secondaires du traitement etdiminution du risque de malformations congenitales en debut de grossesse
EP1891959A1 (fr)	2008-02-27	Préparations contraceptives pour diminuer le risque d'erreurs innées
MXPA98004683A (en)	1999-09-20	The use of tetrahydrofolates in a natural stereoisomeric form for the production of an adequate pharmaceutical preparation to influence the homocysteine level, particularly to help in the homociste remedy
HK1078780B (en)	2011-12-16	Pharmaceutical compositions comprising one or more steroids, one or more tetrahydrofolate components and vitamin b12
HK1156850A (en)	2012-06-22	The use of tetrahydrofolates in natural stereoisomeric form for the production of a pharmaceutical preparation